ScholarLens Back to search
2012•Unpublished venueRequires access

FDA approves perampanel as adjunctive treatment for partial-onset seizures in patients with epilepsy aged 12 years and older

From staff reports

Open publisher page 0 citations

Abstract

FDA has approved perampanel (Fycompa, Eisai), an AMPA receptor antagonist, as an adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients aged 12 years and older who have epilepsy.

About this research paper

What this paper is about

FDA has approved perampanel (Fycompa, Eisai), an AMPA receptor antagonist, as an adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients aged 12 years and older who have epilepsy.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

FDA has approved perampanel (Fycompa, Eisai), an AMPA receptor antagonist, as an adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients aged 12 years and older who have epilepsy.

Key concepts: Perampanel, Medicine, Adjunctive treatment, Partial epilepsy, Epilepsy, Antagonist, partial seizures, Pediatrics

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
FDA approves perampanel as adjunctive treatment for partial-onset seizures in patients with epilepsy aged 12 years and older — Research Paper | ScholarLens